Contracts signed by Locumwise and Dr Jazebi (FOI)
Contracts signed by Locumwise and Dr Jazebi (FOI)Produced by the Freedom of Information office
Authored by Government of Jersey and published on 22 July 2022.
Prepared internally, no external costs.
How many employment-related contracts has Dr Helmi Jazebi signed with Government?
How many contracts have Locumwise LTD signed with the government?
Please provide a copy of each contract signed with Dr Helmi Jazebi, and each contract signed with Locumwise Ltd.
Have the terms of any of these contracts ever been varied / updated?
If so, please state when, the nature of each variation, and provide a copy of the updated document.
Dr Helmi Jazebi has a contract with the Government of Jersey Health and Community Services Department as a Locum Consultant in Rheumatology for the period 14th February 2022 to 2nd September 2022 inclusive.
The Government of Jersey Health and Community Services Department have no contracts with Locumwise Ltd.
No contracts exist with Locumwise Ltd., as per response to question B.
The contract of services is a commercial document and as such, Health and Community Services (HCS) considers that its disclosure would likely prejudice the commercial interests of the department, or others. Therefore, Article 33 of the Freedom of Information (Jersey) Law 2011 has been applied to the request to supply details of Dr Helmi Jazebi's contract.
The terms of Dr Jazebi's contract were agreed prior to commencement of this Locum assignment and have not varied.
Not applicable, as per response to question D.
Article 33 - Commercial interests
Information is qualified exempt information if –
(a) it constitutes a trade secret; or
(b) its disclosure would, or would be likely to, prejudice the commercial interests of a person (including the scheduled public authority holding the information).
Public Interest Test
Article 33 is a qualified exemption and as such we have conducted a prejudice test as required by law. Disclosing information relating to contractual service arrangements is likely to prejudice the commercial interests of HCS and others. When considering the application of this exemption, HCS has determined that whilst it is in the public interest to disclose information, this is outweighed by the necessity to limit any impact on its commercial interests in contracting future Locum clinician services and as such, Article 33 has been applied.